Proving the Business Case for the Internet of Things

IoT to track alcohol use by recovering addicts

Steve Rogerson
February 28, 2017
The IoT is to be used for tracking when recovering alcoholics have a sneaky drink, following a partnership between Texas-based MAP Health Management and Soberlink.
The system will remotely track real-time breathalyser results for patients with an alcohol use disorder.
MAP develops technology-enabled ecosystems to improve clinical and financial outcomes for addiction and other behavioural health disorders. Soberlink created an FDA cleared, remote breathalyser used to detect alcohol usage in the USA.
The partnership will launch with a pilot programme beginning in April where some patients whose risk for relapse is continuously measured by MAP's patient engagement technology will be issued a Soberlink breathalyser that links to the patient's MAP profile. The device, which uses facial recognition technology, will send real-time data to MAP's care platform when a patient performs a test with negative results, misses scheduled tests or tests positive for alcohol use.
With this information, MAP's technology will inform the appropriate members of collaborative care teams if a patient is at an elevated risk for relapse or has returned to alcohol use. Ultimately, these data are leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other means of mitigating recidivism and costly treatment episodes.
Of the patients served by MAP's technology platform, 54.6% of all first post-acute treatment relapses involve alcohol, regardless of the patient's drug of choice.
"The number one factor in improving outcomes is early intervention," said Jacob Levenson, CEO of MAP Health Management. “Soberlink's breathalyser enables our ecosystem of patients, providers and health insurance companies to have a real-time understanding of who is at risk. The net result is saved lives and saved dollars.”
Assessing risk and informing care via remote, real-time breathalyser results across large and diverse populations such as those managed by MAP's technology is new to the addiction treatment space.
"We are excited to partner with MAP and deliver our breathalyser technology to their ecosystem," said Brad Keays, CEO of Soberlink Healthcare. “Our FDA cleared device has shown in numerous studies to be a significant factor in improving outcomes. We are very excited to see the actionable data from our devices be utilised by MAP to improve outcomes.”
MAP also recently announced a partnership with Intent Solutions, the makers of TAD, a biometric medication adherence device.
"We will be announcing more powerful partnerships soon that will significantly change how people with substance use disorder are delivered care across the entire treatment continuum," said Levenson.